Swiss National Bank
KRYS icon

Swiss National Bank’s Krystal Biotech KRYS Stock Holding History

Swiss National Bank’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$11.1M Buy
43,000
+100
+0.2% +$26.6K 0.01% 900
2025
Q4 		$10.6M Buy
42,900
+900
+2% +$189K 0.01% 944
2025
Q3 		$7.41M Buy
42,000
+600
+1% +$89.8K ﹤0.01% 1116
2025
Q2 		$5.69M Sell
41,400
-400
-1% -$58.8K ﹤0.01% 1216
2025
Q1 		$7.54M Sell
41,800
-600
-1% -$101K 0.01% 1035
2024
Q4 		$6.64M Buy
42,400
+3,300
+8% +$585K ﹤0.01% 1148
2024
Q3 		$7.12M Buy
39,100
+2,900
+8% +$559K ﹤0.01% 1111
2024
Q2 		$6.65M Hold
36,200
– – ﹤0.01% 1099
2024
Q1 		$6.44M Buy
36,200
+300
+0.8% +$41.7K ﹤0.01% 1138
2023
Q4 		$4.45M Sell
35,900
-3,500
-9% -$388K ﹤0.01% 1360
2023
Q3 		$4.57M Sell
39,400
-2,700
-6% -$329K ﹤0.01% 1330
2023
Q2 		$4.94M Buy
42,100
+3,200
+8% +$327K ﹤0.01% 1324
2023
Q1 		$3.11M Sell
38,900
-4,500
-10% -$354K ﹤0.01% 1565
2022
Q4 		$3.44M Buy
43,400
+800
+2% +$59.4K ﹤0.01% 1544
2022
Q3 		$2.97M Buy
42,600
+1,400
+3% +$101K ﹤0.01% 1601
2022
Q2 		$2.71M Hold
41,200
– – ﹤0.01% 1705
2022
Q1 		$2.74M Buy
41,200
+2,800
+7% +$175K ﹤0.01% 1847
2021
Q4 		$2.69M Buy
38,400
+6,600
+21% +$384K ﹤0.01% 1862
2021
Q3 		$1.66M Buy
31,800
+400
+1% +$23.7K ﹤0.01% 2166
2021
Q2 		$2.13M Buy
31,400
+2,100
+7% +$147K ﹤0.01% 2056
2021
Q1 		$2.26M Buy
29,300
+400
+1% +$29.1K ﹤0.01% 1926
2020
Q4 		$1.73M Hold
28,900
– – ﹤0.01% 1985
2020
Q3 		$1.24M Buy
28,900
+500
+2% +$21.7K ﹤0.01% 1968
2020
Q2 		$1.18M Buy
28,400
+6,600
+30% +$318K ﹤0.01% 2015
2020
Q1 		$943K Buy
21,800
+300
+1% +$15.7K ﹤0.01% 1863
2019
Q4 		$1.19M Buy
21,500
+1,000
+5% +$49.1K ﹤0.01% 2037
2019
Q3 		$712K Hold
20,500
– – ﹤0.01% 2227
2019
Q2 		$826K Buy
+20,500
New +$670K ﹤0.01% 2217

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Swiss National Bank's KRYS Position: Q1 2026 in Review

Swiss National Bank increased its Krystal Biotech (KRYS) stake by 0.23% in Q1 2026, buying an estimated $26.6K and bringing the position to 43,000 shares worth $11.1M. The position accounts for 0.01% of the portfolio, ranked #900.

Swiss National Bank first reported a position in KRYS in Q2 2019 and has held it in 28 quarters since. 367 funds tracked by Wall St. Rank hold KRYS as of Q1 2026.

  • Swiss National Bank held 43,000 shares of Krystal Biotech worth $11.1M as of Q1 2026.
  • Swiss National Bank bought 100 Krystal Biotech shares in Q1 2026, an estimated $26.6K.
  • Krystal Biotech made up 0.01% of Swiss National Bank's portfolio in Q1 2026, its #900 holding.
  • Swiss National Bank first reported a position in Krystal Biotech in Q2 2019 and has held it in 28 quarters since.
  • 367 funds tracked by Wall St. Rank held Krystal Biotech as of Q1 2026.

Based on Swiss National Bank's 13F filing for Q1 2026, filed 7 May 2026.